Maria Belimezi
Overview
Explore the profile of Maria Belimezi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zouvelou V, Michail M, Belimezi M, Haroniti A, Zisimopoulou P
Neuromuscul Disord
. 2022 Aug;
32(10):847-850.
PMID: 36028368
Two thymoma-associated myasthenia gravis patients with chronic well-controlled disease but an unexpected increase in anti-nAChR autoantibodies titer are reported. The specificity of anti-nAChR autoantibodies directed against extracellular parts of the...
2.
Michail M, Zouvelou V, Belimezi M, Haroniti A, Zouridakis M, Zisimopoulou P
Front Neurol
. 2022 Apr;
13:858998.
PMID: 35418927
Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies targeting components of the postsynaptic membrane of the neuromuscular junction (NMJ), leading to neuromuscular transmission deficiency. In the vast majority...
3.
Belimezi M, Kalliaropoulos A, Mentis A, Chrousos G
J Clin Pathol
. 2021 Sep;
76(3):166-171.
PMID: 34526372
Aims: The laboratory diagnosis of demyelinating inflammatory disorders (DIDs) relies on both intrathecal oligoclonal band (OCB) positivity and IgG index. Although OCB typing remains the gold-standard test for DIDs, it...
4.
Belimezi M, Kalliaropoulos A, Jimenez J, Garcia I, Mentis A, Chrousos G
Clin Neurol Neurosurg
. 2021 Aug;
208:106847.
PMID: 34343914
Objective: Myasthenia gravis (MG) is a typical B-cell-mediated neuromuscular junction disease that can be classified into seropositive and seronegative subtypes. Association of patients' age at sampling and sex with the...
5.
Zouvelou V, Michail M, Belimezi M, Zisimopoulou P
Muscle Nerve
. 2021 Jan;
63(4):E36-E37.
PMID: 33471417
No abstract available.
6.
Zouvelou V, Kyriazi S, Rentzos M, Belimezi M, Micheli M, Tzartos S, et al.
Muscle Nerve
. 2013 Jan;
47(3):465-6.
PMID: 23322599
No abstract available.
7.
Zhang B, Tzartos J, Belimezi M, Ragheb S, Bealmear B, Lewis R, et al.
Arch Neurol
. 2011 Dec;
69(4):445-51.
PMID: 22158716
Objectives: To determine whether patients with myasthenia gravis (MG) have serum antibodies to lipoprotein-related protein 4 (LRP4), a newly identified receptor for agrin that is essential for neuromuscular junction formation,...
8.
Pavlidou A, Dalamaga M, Kroupis C, Konstantoudakis G, Belimezi M, Athanasas G, et al.
World J Gastroenterol
. 2011 Apr;
17(12):1614-21.
PMID: 21472129
Aim: To investigate three isoforms of survivin in colorectal adenocarcinomas. Methods: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice...
9.
Papakyriakou A, Katsarou M, Belimezi M, Karpusas M, Vourloumis D
ChemMedChem
. 2009 Nov;
5(1):118-29.
PMID: 19921722
Substantial evidence over the last decades has implicated uncontrolled angiogenesis with various pathological states, including cancer. Vascular endothelial growth factor (VEGF) plays a critical role in its regulation. Because the...
10.
Mamalaki A, Gritzapis A, Kretsovali A, Belimezi M, Papamatheakis J, Perez S, et al.
Cancer Immunol Immunother
. 2003 Apr;
52(8):513-22.
PMID: 12715240
To broaden the applicability of adoptive cellular immunotherapy against HER-2/neu overexpressing human cancers, we constructed a chimeric scFv/gamma gene composed of the variable regions of a HER-2/neu specific monoclonal antibody...